Protein Engineering

English
Strategic Objectives

1. To give solutions to two major health challenges for the European population:

No-mutagenic and most effective new drugs for the treatment of cancer
Deepen in the mechanism of neurodegenerative diseases caused by protein aggregation processes with the ultimate goal to achieve in future potential inhibitors of these pathological processes.

2. Technology transfer: patents of improved forms of antitumor drugs.

Main lines of research

- Development of antitumor drugs not mutagenic for the treatment of ovarian cancer and non-microcitic lung cancer.
- Study of structural and aggregation determinants of the proteins Apoptin and TDP-43, using nuclear magnetic resonance and isotope labeling of the fragments involved in the aggregation processes that lead to apoptosis.

 

Group Leaders

Antoni Benito and Marc Ribó
 
Senior researchers
 
Maria Vilanova
 
Post-doctorate researchers
 
Jessica Castro
Anna Vert
 
Post-graduate researchers
 
Mariona Callís
 
Glòria García
 
Veronica Gordo
 
Santiago Ruiz
 
David Soler
 
 
Geoposicio: 

Are you investigator?

English

If you research if you are interested in helping with any of our research groups, fill out this form. We will contact you as soon as possible. Thank you.

Send us your details

Read More